DRRX
DURECT Corp
$
0.000
- Overview
- Forecast
- Valuation
- Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
42.37M
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
31.04M
EV
52.79M
EV/OCF(TTM)
--
P/S(TTM)
35.78
DURECT Corporation is a late-stage biopharmaceutical company. The Company is engaged in the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Its lead drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in alcoholic hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Therapy designation, and metabolic dysfunction-associated steatohepatitis (MASH) is also being explored. Its commercial pharmaceutical product includes POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology. It has developed a proprietary drug product for the treatment of ADHD called Methydur.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
250.00K
-79.37%
--
--
300.00K
-84.43%
--
--
320.00K
-85.26%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for DURECT Corporation (DRRX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 208.06%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+208.06%
In Past 3 Month
1 Analyst Rating
Wall Street analysts forecast DRRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRRX is 2.50 USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
Current: 0.000
Low
2.50
Averages
2.50
High
2.50
Current: 0.000
Low
2.50
Averages
2.50
High
2.50
Northland
Outperform -> Market Perform
downgrade
$2.50
2025-07-29
Reason
Northland
Price Target
$2.50
2025-07-29
downgrade
Outperform -> Market Perform
Reason
Northland downgraded Durect (DRRX) to Market Perform from Outperform with a $2.50 price target after Bausch Health (BHC) announced a definitive agreement to indirectly acquire Durect for $1.75 per share in an all-cash transaction for an upfront consideration of approximately $63M at closing, with the potential for two additional net sales milestone payments of up to $350M in the aggregate if achieved.
HC Wainwright & Co.
Ed Arce
Hold
Reiterates
n/a
2025-03-27
Reason
HC Wainwright & Co.
Ed Arce
Price Target
n/a
2025-03-27
Reiterates
Hold
Reason
HC Wainwright & Co.
Ed Arce
Hold
Reiterates
n/a
2024-11-14
Reason
HC Wainwright & Co.
Ed Arce
Price Target
n/a
2024-11-14
Reiterates
Hold
Reason
HC Wainwright & Co.
Ed Arce
Hold
Reiterates
n/a
2024-09-26
Reason
HC Wainwright & Co.
Ed Arce
Price Target
n/a
2024-09-26
Reiterates
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for DURECT Corp (DRRX.O) is -2.81, compared to its 5-year average forward P/E of -4.39. For a more detailed relative valuation and DCF analysis to assess DURECT Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.39
Current PE
-2.81
Overvalued PE
-0.39
Undervalued PE
-8.40
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
13.82
Current PS
54.71
Overvalued PS
27.89
Undervalued PS
-0.25
Financials
Annual
Quarterly
FY2025Q2
YoY :
-30.80%
447.00K
Total Revenue
FY2025Q2
YoY :
-33.17%
-2.80M
Operating Profit
FY2025Q2
YoY :
-44.00%
-2.27M
Net Income after Tax
FY2025Q2
YoY :
-41.67%
-0.07
EPS - Diluted
FY2025Q2
YoY :
-51.96%
-1.76M
Free Cash Flow
FY2025Q2
YoY :
+2.72%
98.43
Gross Profit Margin - %
FY2025Q2
-842.85
FCF Margin - %
FY2025Q2
YoY :
-19.08%
-506.71
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
3
398.0K
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
3
398.0K
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
DRRX News & Events
Events Timeline
2025-08-26 (ET)
2025-08-26
08:23:02
Bausch Health extends its tender offer for Durect.
2025-08-12 (ET)
2025-08-12
16:33:53
Durect reports Q2 cont ops EPS (7c) vs. (13c) last year
2025-07-29 (ET)
2025-07-29
07:18:54
Bausch Health to acquire Durect for $1.75 per share in cash upfront
Sign Up For More Events
Sign Up For More Events
News
8.5
09-11NASDAQ.COMBausch Health Finalizes $63 Million Purchase of DURECT, Enhancing AH Therapy Portfolio
7.0
08-18PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VBTX, PVBC, DRRX on Behalf of Shareholders
8.5
08-18Globenewswire$HAREHOLDER NOTICE: M&A Class Action Firm Ongoing Investigation into the Merger of VBTX, CFSB, PVBC, and DRRX
Sign Up For More News
People Also Watch
IGC
IGC Pharma Inc
0.400
USD
-2.20%
NAII
Natural Alternatives International Inc
3.030
USD
-2.88%
NISN
Nisun International Enterprise Development Group Co Ltd
4.240
USD
+10.13%
PZG
Paramount Gold Nevada Corp
1.200
USD
+9.09%
CVV
CVD Equipment Corp
3.280
USD
+3.47%
XCUR
Exicure Inc
3.720
USD
-3.13%
CPSH
CPS Technologies Corp
3.650
USD
+5.80%
MRKR
Marker Therapeutics Inc
0.900
USD
-5.26%
NXGL
Nexgel Inc
2.530
USD
-2.69%
FAQ
What is DURECT Corp (DRRX) stock price today?
The current price of DRRX is 0 USD — it has decreased -1.05 % in the last trading day.
What is DURECT Corp (DRRX)'s business?
What is the price predicton of DRRX Stock?
What is DURECT Corp (DRRX)'s revenue for the last quarter?
What is DURECT Corp (DRRX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for DURECT Corp (DRRX)'s fundamentals?
How many employees does DURECT Corp (DRRX). have?